Acousys Biodevices Inc, based in Ann Arbor, MI, is a pioneering company specializing in the detection of circulating tumor cells (CTCs) for predicting cancer recurrence and metastasis. Their advanced technology, the Acousys CTC detection system, has demonstrated remarkable sensitivity in identifying melanoma cells in patients with stage I-III malignant melanoma up to 8 years before tumor detection, making it an invaluable tool for early disease monitoring and personalized treatment choices.
With their cutting-edge photoacoustic flow cytometry technology, Acousys Biodevices is at the forefront of clinical utility in CTC detection. Their system not only detects and captures rare CTCs for analysis of drug sensitivity but also holds the potential to sound the alarm on early melanoma metastasis. As a leader in the field, Acousys Biodevices is dedicated to advancing cancer research and improving patient outcomes through their innovative approach.
Generated from the website